Cudetaxestat
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 15, 2020 (NCT04146805)
Timeline
Indications
Mechanism of action
- AutotaxinINHIBITOR
ENPP2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCCn1cc(-n2c(Cl)c(Sc3cccc(C(=O)O)c3F)c3ccc(Cl)c(F)c32)cn1- Mol. weight
- 482.34 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4802146 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05373914 | Phase 2 | May 31, 2022 | Blade Therapeutics |
| NCT04939467 | Phase 1 | Oct 15, 2021 | Advanced Pharma CR, LLC, Blade Therapeutics |
| NCT04814472 | Phase 1 | May 16, 2021 | Blade Therapeutics, Scientia Clinical Research Limited Sydney |
| NCT04814498 | Phase 1 | May 3, 2021 | Blade Therapeutics, Nucleus Network Ltd |
| NCT04146805 | Phase 1 | Jan 15, 2020 | Blade Therapeutics |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Blade Therapeutics | For profit | 5 | 5 | 2 | 2020 |
| Advanced Pharma CR, LLC | For profit | 1 | 0 | 1 | 2021 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2021 |
| Scientia Clinical Research Limited Sydney | For profit | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1